What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of investigation include Internal medicine, Surgery, Gastroenterology, Pathology and Lymphoma.
Internal medicine is closely attributed to Oncology in his research.
His Oncology study combines topics in areas such as Refractory, Cytarabine, Survival rate, Immunology and Rituximab.
His work on Imatinib mesylate and Imatinib as part of general Immunology research is frequently linked to CXCR4, thereby connecting diverse disciplines of science.
His Pathology study combines topics from a wide range of disciplines, such as Ex vivo, Hematology, Cytogenetics, Fluorescence in situ hybridization and Galactomannan.
His research in Lymphoma focuses on subjects like Neutropenia, which are connected to Inotuzumab ozogamicin, Calicheamicin, Aspergillosis, Mycosis and Pharmacology.
His most cited work include:
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2888 citations)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)
- A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome (1452 citations)
What are the main themes of his work throughout his whole career to date?
Gregor Verhoef mainly investigates Internal medicine, Pathology, Oncology, Lymphoma and Immunology.
His Internal medicine research includes themes of Gastroenterology and Surgery.
In his study, which falls under the umbrella issue of Pathology, Karyotype is strongly linked to Cytogenetics.
The various areas that Gregor Verhoef examines in his Oncology study include Cytarabine, Myeloid leukemia, Refractory and Phases of clinical research.
His Lymphoma study integrates concerns from other disciplines, such as Positron emission tomography, Nuclear medicine, Cancer research and Survival analysis.
His Rituximab research includes elements of Vincristine and Mantle cell lymphoma.
He most often published in these fields:
- Internal medicine (42.69%)
- Pathology (20.04%)
- Oncology (17.84%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (42.69%)
- Lymphoma (17.84%)
- Rituximab (9.42%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Lymphoma, Rituximab, Cancer research and Oncology.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery.
Lymphoma is a subfield of Pathology that Gregor Verhoef tackles.
His studies in Rituximab integrate themes in fields like CHOP, Vincristine, Mantle cell lymphoma and Prednisone.
As part of one scientific family, he deals mainly with the area of Oncology, narrowing it down to issues related to the Open label, and often B-Cell Non-Hodgkin Lymphoma.
His work in Chemotherapy addresses issues such as Immunology, which are connected to fields such as Stem cell.
Between 2012 and 2021, his most popular works were:
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma (231 citations)
- Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. (123 citations)
- Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. (115 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Internal medicine, Lymphoma, Oncology, Rituximab and Gastroenterology are his primary areas of study.
Many of his studies involve connections with topics such as Surgery and Internal medicine.
His studies deal with areas such as Cancer research, Comparative genomic hybridization and Single Center as well as Lymphoma.
He has researched Oncology in several fields, including Post transplant, Cohort study and Chemotherapy.
The Rituximab study combines topics in areas such as CHOP, Vincristine and Transplantation.
His Gastroenterology study also includes fields such as
- Survival analysis which connect with Aggressive lymphoma,
- International Prognostic Index which connect with Progression-free survival.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
